LYSA at ASH 2022

LYSA studies presented at the 64th ASH meeting

The 64th ASH Annual Meeting and Exposition will be held December 10-13, 2022 in New Orleans, Louisiana.

This year, the scientific production and studies of the LYSA will be particularly honored during this congress since 15 abstracts in the form of oral communications and posters will be presented.

8 oral communications

Saturday, December 10, 2022

  • 166 : Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-ineligible patients : Primary analysis of ALYCANTE, a Phase 2 LYSA Study

12h45 – Roch Houot


Sunday, December 11, 2022

  • 449 : Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, RCHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from LYSA

10h30 – David Sibon

  • 553 : Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

12h00 – Federico Erbella / Roberta Di Blasi

  • 545 : A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

13h00 – Herve Ghesquieres


Monday, December 12, 2022

  • 722 : Frequent Alterations of Driver Genes in Chromosome X and their Clinical Relevance in Extranodal NK/T-cell Lymphoma

10h45 – Yuta Ito / Lucile Couronné / Amira Marouf

  • 767 : Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A LYSA Study from the DESCAR-T Registry

11h30 – Jean Lemoine

  • 956 : Addition of Brentuximab vedotin to gemcitabine in Relapsed or Refractory T-cell Lymphoma: Final analysis of a LYSA Multicenter, Phase II Study. “The TOTAL Trial”

16h45 – Olivier Tournilhac

  • 959 : Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma: Final Analysis of the ORACLE Phase III Study

17h30 – François Lemonnier / Jehan Dupuis

7 posters

Saturday, December 10, 2022

  • 1596 : The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK Positive ALCL Treated By CHOEP: A Lysa Study

David Sibon – Session 624 – 17H30-19h30

  • 2282 : Evaluation of participation in a prospective real-life multicentric cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for newly diagnosed lymphoma patients over one year in a hematology department – POSTER

Caroline Le Lan – Session 905 – 17h30-19h30

  • 1652 : Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry

Hedi Bensaber – Session 627 – 17h30-19h30

  • 2226 : CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a LYSA Study Based on the DESCAR-T registry

Gilles Crochet – Session 705 – 17h30-19h30


Sunday, December 11, 2022

  • 2878 : Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the FLIRT Clinical Trial, a Lysa Study

Mikael Roussel – Session 622 – 18h-20h

  • 2883 : Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Anne-Ségolène Cottereau – Session 623 – 18h-20h

  • 2948 : Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final results of 18 patients treated at RP2D of Selinexor in the SELINDA Phase Ib LYSA Study

Marie Maerevoet – Session 626 – 18h-20h